The 2026 ACC/AHA multisociety dyslipidemia guideline updates recommend adding icosapent ethyl for statin-treated patients with triglyceride levels between 135 and 499 mg/dL to reduce residual cardiovascular risk. The guideline recognizes that achieving LDL-C targets alone does not eliminate CV events and endorses complementary therapies proven to lower event rates.

Icosapent ethyl has been prescribed over 30 million times and demonstrated a 25% reduction in heart attack and stroke risk when added to statin therapy in high-risk patients with elevated triglycerides. The guideline differentiates therapies that lower biomarkers from those proven to reduce atherosclerotic cardiovascular disease events, highlighting the unique benefits of Vascepa.

This guideline validation could drive increased adoption of Vascepa in clinical practice and expand Amarin’s market penetration in the U.S. and internationally. Enhanced use of icosapent ethyl may also carry favorable economic implications by potentially lowering hospitalization and procedure rates associated with CV events.